What changed: Hepatocellular carcinoma
Every dated change on the records linked to Hepatocellular carcinoma, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
September 2026 · 1
July 2026 · 1
January 2026 · 1
2026 · 2
March 2025 · 1
2025 · 1
May 2024 · 2
- 2024-05RegulatoryCamrelizumab + rivoceranibCamrelizumab + rivoceranib: complete response letter (US)
First CRL: manufacturing inspection findings
- 2024-05RegulatoryCamrelizumabCamrelizumab: complete response letter (US)
Complete response letter for camrelizumab + rivoceranib in HCC (manufacturing/inspection)
2024 · 4
- 2024Trial resultCheckMate 9DWCheckMate 9DW reported
OS 23.
- 2024Trial resultEMERALD-1EMERALD-1 reported
PFS HR 0.
- 2024Trial resultLEAP-012LEAP-012 reported
PFS HR 0.
- 2024MilestoneEMERALD-1EMERALD-1 and LEAP-012: TACE + systemic therapy improves PFS; HIMALAYA 5-year OS 19.6%
A milestone in how this cancer is treated.
2023 · 7
- 2023ApprovalCamrelizumab + rivoceranibCamrelizumab + rivoceranib approved in China
First-line unresectable HCC
- 2023ApprovalRivoceranib (apatinib)Rivoceranib (apatinib) approved in China
First-line unresectable hepatocellular carcinoma with camrelizumab (CARES-310)
- 2023GuidelineHepatocellular carcinomaGuideline AASLD 2023 / EASL 2025: Prevention
Universal HBV vaccination; antiviral suppression of HBV; direct-acting antiviral cure of HCV; alcohol and metabolic risk reduction. (NCCN Hepatobiliary Cancers)
- 2023GuidelineHepatocellular carcinomaGuideline AASLD 2023 Practice Guidance: Surveillance
Six-monthly ultrasound ± AFP in cirrhosis and high-risk HBV carriers; abbreviated MRI where ultrasound is inadequate.
- 2023Trial resultCARES-310CARES-310 reported
OS 23.
- 2023Trial resultIMbrave050IMbrave050 reported
Interim RFS HR 0.
- 2023Trial resultLow-dose olanzapine for cancer anorexia (Tata Memorial)Low-dose olanzapine for cancer anorexia (Tata Memorial) reported
Weight gain over 5%: 60% vs 9%; appetite improvement 43% vs 13%.
October 2022 · 1
2022 · 4
- 2022ApprovalTremelimumabTremelimumab approved in US
Metastatic NSCLC without EGFR/ALK, with durvalumab and platinum chemotherapy; unresectable HCC with durvalumab
- 2022Trial resultHIMALAYAHIMALAYA reported
OS HR 0.
- 2022Trial resultLEAP-002LEAP-002 reported
OS HR 0.
- 2022MilestoneHIMALAYAHIMALAYA: STRIDE approved; BCLC update adds systemic therapy for some BCLC-B
A milestone in how this cancer is treated.
2021 · 4
- 2021ApprovalDonafenibDonafenib approved in China
First-line unresectable hepatocellular carcinoma (ZGDH3)
- 2021ApprovalSintilimabSintilimab approved in China
First-line non-squamous NSCLC with pemetrexed and platinum (ORIENT-11); first-line squamous NSCLC with gemcitabine and platinum (ORIENT-12); first-line unresectable hepatocellular carcinoma with IBI305 (ORIENT-32)
- 2021Trial resultORIENT-32ORIENT-32 reported
OS HR 0.
- 2021Trial resultZGDH3 (donafenib vs sorafenib)ZGDH3 (donafenib vs sorafenib) reported
OS 12.
May 2020 · 2
2020 · 4
- 2020ApprovalRivoceranib (apatinib)Rivoceranib (apatinib) approved in China
Advanced hepatocellular carcinoma after prior systemic therapy
- 2020Trial resultIMbrave150IMbrave150 reported
OS 19.
- 2020MilestoneIMbrave150IMbrave150: atezolizumab + bevacizumab beats sorafenib
First regimen to improve OS over sorafenib; new standard.
- 2020MilestoneAtezolizumabIMbrave150: atezolizumab-bevacizumab
A milestone in how this cancer is treated.
2019 · 4
- 2019ApprovalCabozantinibCabozantinib approved in US
HCC previously treated with sorafenib
- 2019ApprovalCamrelizumabCamrelizumab approved in China
Classical Hodgkin lymphoma; subsequently HCC, NSCLC, ESCC (second line 2020, first line with chemotherapy 2021), nasopharyngeal
- 2019ApprovalRamucirumabRamucirumab approved in US
HCC with AFP ≥400 ng/mL after sorafenib
- 2019ApprovalTislelizumabTislelizumab approved in China
Classical Hodgkin lymphoma (first); subsequently urothelial, NSCLC, HCC, ESCC, gastric, nasopharyngeal
2018 · 4
- 2018ApprovalLenvatinibLenvatinib approved in US
First-line unresectable HCC
- 2018Trial resultCELESTIALCELESTIAL reported
OS 10.
- 2018Trial resultREFLECTREFLECT reported
OS 13.
- 2018MilestoneREFLECTREFLECT: lenvatinib non-inferior first line; CELESTIAL: cabozantinib second line
A milestone in how this cancer is treated.
2017 · 4
- 2017ApprovalRegorafenibRegorafenib approved in US
HCC previously treated with sorafenib
- 2017Trial resultRESORCERESORCE reported
OS 10.
- 2017Trial resultSARAH and SIRveNIBSARAH and SIRveNIB reported
OS not improved; fewer adverse events.
- 2017MilestoneRESORCERESORCE: regorafenib, first second-line benefit; SARAH/SIRveNIB negative for Y-90 vs sorafenib
A milestone in how this cancer is treated.